Radar›Companies›Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 30
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Prism Readiness Cohort 30

A five-company pharmaceutical preparations cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 02 September 2026Not investment adviceRanked by Prism readiness
Readiness leaderMacroGenics · 34
Strongest available pathCytomX Therapeutics · -26.9%
Widest latest marginCytomX Therapeutics · -22.8%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1MGNX · Nasdaq

MacroGenics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2000Rockville, Maryland$275.2M market cap
View full Companies Radar profile
34Cautious
Snapshot price$4.32as of page date
Monthly-close return-79.4%five-year window
FY2025 revenue$0.15BMACROGENICS INC
Net margin-49.9%FY2025
P/E snapshot-2.9xone ratio, not a verdict
Prism attention49.9%share across these five
Filing track recordRevenue, USD billions
+93.0%
$0$0.1B$0.1B$0.2BFY2021: $0.077BFY2022: $0.152BFY2023: $0.059BFY2024: $0.150BFY2025: $0.149B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 17.9%
52-week position80% through range
$1.29$5.08
News mentions1.7K
Community mentions29partial coverage
U.S.-scope patents1782
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal32/100
Management stability90/100
Market position3/100
Capital-event signal42/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 1 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2CTMX · Nasdaq

CytomX Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2008Santa Barbara, California$810.6M market cap
View full Companies Radar profile
33Cautious
Snapshot price$3.72as of page date
Monthly-close return-26.9%five-year window
FY2025 revenue$0.08BCytomX Therapeutics, Inc.
Net margin-22.8%FY2025
P/E snapshot-7.9xone ratio, not a verdict
Prism attention17.4%share across these five
Filing track recordRevenue, USD billions
+9.5%
$0$0.0B$0.1B$0.1BFY2021: $0.070BFY2022: $0.053BFY2023: $0.101BFY2024: $0.138BFY2025: $0.076B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.3%
52-week position29% through range
$1.90$8.21
News mentions579
Community mentions4partial coverage
U.S.-scope patents825
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal15/100
Management stability90/100
Market position0/100
Capital-event signal69/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3EMMA · OTC

Emmaus Medical

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2000Torrance, California$5.0M market cap
View full Companies Radar profile
33Cautious
Snapshot price$0.07as of page date
Monthly-close return-95.6%five-year window
FY2025 revenue$0.01BEmmaus Life Sciences, Inc.
Net margin-60.2%FY2025
Prism attention5.9%share across these five
Filing track recordRevenue, USD billions
-39.6%
$0$0.0B$0.0B$0.0BFY2021: $0.021BFY2022: $0.018BFY2023: $0.030BFY2024: $0.017BFY2025: $0.012B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -11.8%
52-week position75% through range
$0.01$0.09
News mentions197
Community mentions0partial coverage
U.S.-scope patents49
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal26/100
Management stability90/100
Market position10/100
Capital-event signal48/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 1 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4PRPH · OTC

ProPhase Labs

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1989Doylestown, Pennsylvania$0.3M market cap
View full Companies Radar profile
33Cautious
Snapshot price$0.02as of page date
Monthly-close return-100.0%five-year window
FY2024 revenue$0.01BProPhase Labs, Inc.
Net margin-788.2%FY2024
Prism attention11.6%share across these five
Filing track recordRevenue, USD billions
-53.4%
$0$0.0B$0.1B$0.1BFY2020: $0.015BFY2021: $0.079BFY2022: $0.123BFY2023: $0.044BFY2024: $0.007B20202021202220232024
FY2020–FY2024 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -17.4%
52-week position0% through range
$0.02$6.70
News mentions386
Community mentions0partial coverage
U.S.-scope patents11
Prism Insights

What sits behind the readiness signal

Observed risk 2/100higher means more observed risk
Earnings signal27/100
Management stability90/100
Market position15/100
Capital-event signal35/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 3 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5CUE · Nasdaq

Cue Biopharma

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2015Cambridge, Massachusetts$195.8M market cap
View full Companies Radar profile
32Cautious
Snapshot price$26.96as of page date
Monthly-close return-93.8%five-year window
FY2025 revenue$0.03BCue Biopharma, Inc.
Net margin-96.9%FY2025
Prism attention15.2%share across these five
Filing track recordRevenue, USD billions
+83.8%
$0$0.0B$0.0B$0.0BFY2021: $0.015BFY2022: $0.001BFY2023: $0.005BFY2024: $0.009BFY2025: $0.027B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 16.4%
52-week position54% through range
$4.98$45.50
News mentions507
Community mentions0partial coverage
U.S.-scope patents491
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal39/100
Management stability78/100
Market position0/100
Capital-event signal25/100
Innovation pulse3/100
Management signal

No leadership-churn flag in the model; 6 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

CytomX Therapeutics
-26.9%
MacroGenics
-79.4%
Cue Biopharma
-93.8%
Emmaus Medical
-95.6%
ProPhase Labs
-100.0%

Latest revenue

USD billions, official filing scope shown on each company card.

MacroGenics
$0.15B
CytomX Therapeutics
$0.08B
Cue Biopharma
$0.03B
Emmaus Medical
$0.01B
ProPhase Labs
$0.01B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

CytomX Therapeutics
-22.8%
MacroGenics
-49.9%
Emmaus Medical
-60.2%
Cue Biopharma
-96.9%
ProPhase Labs
-788.2%

Prism news attention

Normalized share across these five names; attention is not quality.

MacroGenics
49.9%
CytomX Therapeutics
17.4%
Cue Biopharma
15.2%
ProPhase Labs
11.6%
Emmaus Medical
5.9%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

MacroGenics leads the conversation

It holds 49.9% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.15B.

Price path

CytomX Therapeutics leads the available price paths

Its monthly-close return is -26.9% for the five-year window. At the other end, ProPhase Labs is -100.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

CytomX Therapeutics has the widest latest margin

Its FY2025 net margin is -22.8%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

CytomX Therapeutics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -7.9x while its five-year window price return is -26.9%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · MGNX

MacroGenics

1,666available Prism news records

Prism top themes

Legal, arbitration & regulatory
53
Price action & investor response
33
Capital allocation & transactions
18
Earnings & financial performance
17
Leadership & governance
10

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-60.0%177 latest 12m vs 442 prior 12m
2024-01: 3 mentions2024-02: 16 mentions2024-03: 8 mentions2024-04: 18 mentions2024-05: 36 mentions2024-06: 14 mentions2024-07: 51 mentions2024-08: 120 mentions2024-09: 81 mentions2024-10: 21 mentions2024-11: 15 mentions2024-12: 13 mentions2025-01: 2 mentions2025-02: 86 mentions2025-03: 20 mentions2025-04: 8 mentions2025-05: 18 mentions2025-06: 7 mentions2025-07: 3 mentions2025-08: 14 mentions2025-09: 14 mentions2025-10: 10 mentions2025-11: 16 mentions2025-12: 8 mentions2026-01: 8 mentions2026-02: 25 mentions2026-03: 23 mentions2026-04: 27 mentions2026-05: 27 mentions2026-06: 2 mentions2024-012026-06

Machine-classified coverage tone

88.4% positive+33.5 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

class action securities litigation 35cancer biomarkers 33angiogenesis inhibitors 27adc therapeutics 22minority shareholder protections 19derivative lawsuit defense 14shareholder oppression claims 14stock performance 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-06-01 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

MGNX

MacroGenics

29 mentions
Stock and valuation
18
Products, pricing and logistics
4
Workplace and hiring
1

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 29 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

MGNX

MacroGenics

through 2026-03-09
Earnings releases 9Lawsuits 6Leadership changes 5Listing / IPO 2Asset acquisitions 1
  1. Earnings releases

    Cash, cash equivalents and marketable securities of $189.9 million as of December 31, 2025; cash runway guidance remains into late 2027.

  2. Leadership changes

    MacroGenics promoted Eric Risser to president and CEO.

  3. Listing / IPO

    Macrogenics Inc. closed its IPO for gross proceeds of about $92 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CTMX

CytomX Therapeutics

through 2026-01-14
Earnings releases 3Company announcements 2Leadership changes 2Board updates 1Business contracts 1
  1. Leadership changes

    Partner Suzanne Zebedee of ON Partners recently placed Rachael Lester as senior vice president and chief business officer of NASDAQ-traded CytomX Therapeutics, Inc. in South San Francisco, CA.

  2. Earnings releases

    CytomX Therapeutics Inc. (CTMX) on Monday reported first-quarter net income of $23.5 million.

  3. Listing / IPO

    Cytomx Therapeutics Inc., of South San Francisco, said it closed its IPO of 7.66 million shares of common stock at $12 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1 million additional shares of common stock. Gross proceeds totaled $92 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

EMMA

Emmaus Medical

through 2025-12-31
Earnings releases 7Company announcements 1Regulatory 1
  1. Regulatory

    Endari® is approved for marketing in the United States, Israel, Kuwait, Qatar, the United Arab Emirates, Bahrain and Oman.

  2. Earnings releases

    Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the year ended December 31, 2024.

  3. Company announcements

    Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, reported today that the filing of its Annual Report on Form 10-K for the year ended December 31, 2023 will be delayed.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PRPH

ProPhase Labs

through 2025-11-18
Earnings releases 14Company announcements 13Listing / IPO 4Leadership changes 3Business contracts 2
  1. Earnings releases

    Analysts estimate that ProPhase Labs will report an earnings per share (EPS) of $-0.11.

  2. Lawsuits

    ProPhase Labs, Inc. announced that its three COVID-19 testing laboratory companies filed for reorganization under Chapter 11 in United States Bankruptcy Court for the District of New Jersey.

  3. Leadership changes

    The company announced the appointment of Stu Hollenshead as Chief Operating Officer

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CUE

Cue Biopharma

through 2026-04-22
Leadership changes 13Earnings releases 8Listing / IPO 2Board updates 1Company announcements 1
  1. Company announcements

    Cue Biopharma, Inc. (Nasdaq: CUE ), a clinical-stage biopharmaceutical company ... today announced that it will implement a 1-for-30 reverse stock split of the issued shares of the company’s common stock, effective at 5:00 p.m. Eastern Time on April 23, 2026.

  2. Board updates

    The six nominees were elected as directors.

  3. Earnings releases

    Cue Biopharma (NASDAQ:CUE – Get Free Report) last posted its quarterly earnings data on Monday, March 16th.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 146–153. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 02 September 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Cue Biopharma has the widest attention-readiness rank gap

It ranks #3 by measured news attention (15.2%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Cue Biopharma in Companies Radar

Cue Biopharma shows a price-operating divergence to inspect

Its displayed filing-revenue change is +83.8% while its available monthly-close return is -93.8%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Cue Biopharma in Companies Radar
Explanations

Attention measures coverage volume, not quality

MacroGenics's 49.9% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open MacroGenics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open MacroGenics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 34/100 score.

Open MacroGenics in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon